Veeva Systems Available For Sale Securities Debt Securities Current increased by 3.3% to $5.14B in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 27.5%, from $4.03B to $5.14B. Over 5 years (FY 2021 to FY 2026), Available For Sale Securities Debt Securities Current shows an upward trend with a 40.7% CAGR.
An increase suggests higher liquidity and a conservative cash management strategy, while a decrease may indicate cash deployment for operations or acquisitions.
This represents the portion of a company's investment portfolio consisting of debt securities that are expected to be so...
Common among large-cap pharmaceutical firms maintaining significant cash reserves for R&D and M&A activities.
current_assets_available_for_sale_securities_debt_securi_87ec82| Q1 '21 | Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $965.45M | $1.20B | $1.20B | $1.24B | $1.60B | $1.78B | $2.16B | $2.22B | $2.52B | $3.13B | $3.20B | $3.32B | $3.57B | $3.72B | $4.02B | $4.03B | $4.10B | $4.47B | $4.98B | $5.14B |
| QoQ Change | — | +24.2% | +0.2% | +3.0% | +29.1% | +11.3% | +21.3% | +2.7% | +13.8% | +24.0% | +2.3% | +3.9% | +7.3% | +4.2% | +8.0% | +0.3% | +1.8% | +9.0% | +11.3% | +3.3% |
| YoY Change | — | — | — | — | +65.6% | +48.4% | +79.6% | +79.0% | +57.7% | +75.7% | +48.3% | +50.0% | +41.5% | +19.0% | +25.6% | +21.3% | +15.0% | +20.3% | +23.9% | +27.5% |